Synergy Biomedical, LLC has announced that it has recently received FDA clearance and will be launching its first bone graft product, BioSphere™ Putty. Utilizing a specialized form of 45S5 bioactive glass with a unique sphere shape and a narrow size range, BioSphere™ Putty provides an optimized bone graft material that outperforms other bioactive products.
Around 15 years ago, I was fortunate enough to study for a Ph.D. with an Entrepreneurial Professor. Five years later, after working on a few healthcare-related projects, we were then fortunate enough to snag an ambitious MBA graduate with an executive retail background, looking for a new challenge, and gained support of doctors.
“Smart” eyewear has just collided with smart vision correction — and no, I’m not talking about the prescription-based versions of Google Glass that are in development. Researchers have taken the concept of Google Glass and applied it to soft contact lenses.
In the near future, a buzz in your belt or a pulse from your jacket may give you instructions on how to navigate your surroundings. Think of it as tactile Morse code: vibrations from a wearable, GPS-linked device that tell you to turn right or left, or stop, depending on the pattern of pulses you feel.
AngioDynamics (Nasdaq:ANGO) has announced the U.S. Food & Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval to conduct a clinical study of the NanoKnife System for the ablation of focal prostate cancer.
Researchers used a flat interface nerve electrode to demonstrate direct sensory feedback. By interfacing with residual nerves in the patient's partial limb, some sense of touch by the fingers is restored. Unlike visual feedback, direct sensory feedback allows patients to move a hand without keeping their eyes on it—enabling simple tasks, like rummaging through a bag for small items, not possible with today's prosthetics.
A more accurate and reliable stroke prediction model has been developed to help physicians decide whether to start blood-thinning treatment for patients with atrial fibrillation, as described in the current online issue of the Journal of the American Heart Association.
Sorin Group Announces First U.S. Implant of PARADYM RF SonR CRT-D for RESPOND CRT IDE Clinical TrialJune 20, 2013 10:00 am | by Business Wire | News | Comments
Sorin Group (MIL:SRN), a global medical device company and leader in the treatment of cardiovascular diseases, announces the first U.S. implant of its PARADYM SonR CRT System for the RESPOND CRT IDE Clinical Trial. Dr. B. A. Smith, Electrophysiologist, Piedmont Heart Institute, Atlanta, GA, performed the procedure on May 30.
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
Researchers at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a new algorithm that can accurately measure the heart rates of people depicted in ordinary digital video by analyzing imperceptibly small head movements that accompany the rush of blood caused by the heart’s contractions.
Product development firm Cambridge Consultants has announced that it is working with the Institute of Metabolic Science (IMS) at Addenbrooke’s Hospital in Cambridge, UK on groundbreaking research to create an artificial pancreas.
Researchers are developing a new type of gripping arm for medical and engineering applications, using the the flexible armor of seahorses as a model. A team at the University of California San Diego says the creature's natural armor plating provides a degree of strength and flexibility that does not exist outside nature. Tara Cleary reports.
Covidien (NYSE: COV), a leading global provider of healthcare products, has announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.
Infinity Compounding has launched its new line of INHIBIT antimicrobial concentrates and compounds. The new INHIBIT antimicrobial additives are based on silver functionalized clay and prevent growth of bacteria, fungus and other microorganisms in a variety of applications.
Much like other medical technology, implants are adapting to a post-depression economy brimming with new materials, new ideas, and ambitious plans for the future. The result is a focus on designing safer, more bio-compatible products for local markets.